Zentalis Pharmaceuticals' (ZNTL) Buy Rating Reiterated at HC Wainwright

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They presently have a $10.00 price target on the stock. HC Wainwright's price target would suggest a potential upside of 423.56% from the company's current price.

Several other equities analysts have also issued reports on ZNTL. UBS Group decreased their target price on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating for the company in a research report on Tuesday, January 28th. Wells Fargo & Company reduced their price target on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating on the stock in a research report on Thursday, January 30th. Finally, Wedbush restated a "neutral" rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Friday, January 24th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $8.24.

Zentalis Pharmaceuticals Trading Up 4.9 %

Shares of NASDAQ:ZNTL traded up $0.09 during midday trading on Monday, hitting $1.91. The company had a trading volume of 1,666,615 shares, compared to its average volume of 1,514,566. Zentalis Pharmaceuticals has a 12 month low of $1.61 and a 12 month high of $16.27. The firm has a fifty day simple moving average of $2.12 and a 200 day simple moving average of $2.91. The stock has a market cap of $136.12 million, a price-to-earnings ratio of -0.77 and a beta of 1.75.

Remove Ads

Insiders Place Their Bets

In other Zentalis Pharmaceuticals news, insider Ingmar Bruns acquired 20,000 shares of Zentalis Pharmaceuticals stock in a transaction dated Thursday, February 6th. The stock was bought at an average cost of $2.28 per share, for a total transaction of $45,600.00. Following the purchase, the insider now directly owns 36,629 shares in the company, valued at approximately $83,514.12. This represents a 120.27 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Jan Skvarka bought 60,000 shares of the stock in a transaction that occurred on Friday, January 31st. The stock was bought at an average cost of $1.72 per share, for a total transaction of $103,200.00. Following the transaction, the director now owns 149,551 shares of the company's stock, valued at $257,227.72. The trade was a 67.00 % increase in their position. The disclosure for this purchase can be found here. Insiders own 3.60% of the company's stock.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Voya Investment Management LLC lifted its stake in Zentalis Pharmaceuticals by 14.1% in the fourth quarter. Voya Investment Management LLC now owns 57,017 shares of the company's stock valued at $173,000 after acquiring an additional 7,058 shares during the last quarter. Wells Fargo & Company MN lifted its stake in Zentalis Pharmaceuticals by 26.8% in the 4th quarter. Wells Fargo & Company MN now owns 34,609 shares of the company's stock valued at $105,000 after purchasing an additional 7,305 shares during the last quarter. Erste Asset Management GmbH bought a new position in Zentalis Pharmaceuticals during the third quarter worth about $37,000. Paloma Partners Management Co acquired a new position in Zentalis Pharmaceuticals during the third quarter worth approximately $37,000. Finally, 49 Wealth Management LLC raised its stake in Zentalis Pharmaceuticals by 81.7% in the third quarter. 49 Wealth Management LLC now owns 22,558 shares of the company's stock valued at $83,000 after buying an additional 10,145 shares during the period.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.